Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Cerubidine
(United States) [Available]Synonyms :
Daunorubicin
Class :
Antibiotics and antineoplastics
Brand Name :
Cerubidine
(United States) [Available]Synonyms :
Daunorubicin
Class :
Antibiotics and antineoplastics
Dosage forms and strength:Â
Powder for injection Â
20 mg Â
Solution Â
5 mg/mlÂ
Acute Lymphoblastic Leukemia(All)Â
Administer a dose of 45 mg/m2 intravenous route once daily on day no. 1, 2, and 3 of the first course
Pediatric Â
Not determined Â
may enhance the immunosuppressive effect of immunosuppressants
may diminish therapeutic effects of the vaccine
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
may increase the serum concentration and adverse effects of daunorubicin by inhibiting BCRP
anthracyclines may decrease the serum concentration of digoxin
increase serum level of daunorubicin by P-glycoprotein efflux transporter
increases serum level of daunorubicin by P-glycoprotein efflux transporter
influenza virus vaccine trivalent
decreases therapeutic effects of influenza vaccine
increase serum level of daunorubicin by P-glycoprotein efflux transporter
interaction increases toxic effects of daunorubicin
interaction increases toxic effects of daunorubicin
increase serum level of daunorubicin by P-glycoprotein efflux transporter
increases serum level of daunorubicin by P-glycoprotein efflux transporter
increases immunosuppressive effects and risk of serious infections
increase myelosuppressive effects by increasing serum concentration of daunorubicin
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the excretion and reduce the effects of daunorubicin
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
may enhance immunosuppressive effects of daunorubicin
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase cardiac toxicity risk
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
may diminish therapeutic effects of the vaccine
may enhance bone marrow suppression
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
enhance cardiac toxicity
may diminish the therapeutic effects of the vaccine
may enhance immunosuppressive effects of daunorubicin
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
decrease the metabolism of daunorubicin and increase serum levels
decrease the metabolism of daunorubicin and increase serum levels
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
may enhance the risk of serious infections due to increased immunosuppressive effects
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
decrease the metabolism of daunorubicin and increase serum levels
decrease the metabolism of daunorubicin and increase serum levels, also increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increases bone marrow suppression
increases cardiac distress risk
increases immunosuppression
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
may enhance the risk of serious infections due to increased immunosuppressive effects
may enhance the risk of serious infections due to increased immunosuppressive effects
may enhance the adverse effects such as bone marrow suppression
increases the effects of daunorubicin by inhibiting BCRP transport
increases the effects of daunorubicin by inhibiting BCRP transport
immunosuppressive drugs may reduce the therapeutic effects of pidotimod
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
may enhance the adverse effects such as bone marrow suppression
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increases the effects of daunorubicin by inhibiting BCRP transport
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increases the effects of daunorubicin by inhibiting BCRP transport
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increases immunosuppressive effects and increases the risk of serious infection
may diminish the therapeutic effects of sipuleucel-T
increases the effects of daunorubicin by inhibiting BCRP transport
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increases the effects of daunorubicin by inhibiting BCRP transport
increase bone marrow suppression
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
It may enhance the effect when combined with tafamidis meglumine
When alprazolam and daunorubicin is used together, this leads to reduction in the alprazolam’s metabolism
When mometasone furoate is used together with daunorubicin, this leads to enhanced risk or seriousness of adverse outcomes
When daunorubicin is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
daunorubicin: it may increase the risk of myelosuppression with sulfamethoxazole
when both drugs are combined, there may be a decreased metabolism of etoposide   
when both the drugs are combined, the risk or severity of adverse effects increases    
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
may increase the risk of cardiotoxicity
cerivastatin: it may decrease the excretion rate of daunorubicin
Actions and Spectrum:Â
Daunorubicin is an anthracycline antibiotic which has anti-neoplastic effects through multiple mechanisms. The inhibition of topoisomerase II enzyme, and disruption of DNA and RNA synthesis. Â
Frequency defined:Â Â
>10%:Â Â
ECG abnormality Â
Ventricular premature contractions Â
Alopecia Â
Nausea Â
Vomiting Â
Weight loss Â
Mucositis Â
1% to 10%:Â
Discoloration of sweat Â
Hyperuricemia Â
Diarrhea Â
Gastrointestinal ulcer Â
Discoloration of saliva Â
<1%Â Â
Anaphylactoid  Â
Cardiac failure Â
Cardiac arrhythmia Â
Black Box Warning:Â Â
None Â
Contraindication/Caution:Â Â
Contraindications Â
Hypersensitivity Â
Renal impairment Â
Hepatic impairment Â
Cautions Â
Renal impairment Â
Hepatic impairment Â
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation: Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Pharmacology:Â Â
Daunorubicin belongs to the anthracycline class which disrupts DNA by inserting itself between base pairs and results in the unwinding of the helix and inhibiting the synthesis of new DNA.Â
Pharmacodynamics:Â Â
This may generate free radicals which modify gene expression control and suppress polymerase activity. Â
Pharmacokinetics:Â Â
Limited information is available on ADME. Â
Administration:Â Â
Daunorubicin is administered intravenously through rapid infusions. Â
Generic Name: daunorubicinÂ
Pronunciation: DAW-noh-ROO-bi-sin
Why do we use Daunorubicin? Â
Daunorubicin is an anthracycline antibiotic primarily used to treat various types of cancer, particularly leukemias. It is effective in the treatment of both acute leukemias (such as acute myeloid leukemia [AML] and acute lymphoblastic leukemia [ALL]) and, in some cases, chronic leukemias. It is commonly included in combination chemotherapy regimens.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
